tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

OVID Stock Latest News

Ovid Therapeutics Secures $175.1M in Private Placement
Company AnnouncementsOvid Therapeutics Secures $175.1M in Private Placement
51m ago
8K
OVID
Morning Movers: Apple shares slip following Jefferies downgrade
PremiumThe Fly
Morning Movers: Apple shares slip following Jefferies downgrade
9h ago
GME
RUM
Ovid Therapeutics prices private placement up to $175M in gross proceeds
PremiumThe Fly
Ovid Therapeutics prices private placement up to $175M in gross proceeds
11h ago
OVID
Ovid Therapeutics announces results for Phase 1 study of OV329
PremiumThe Fly
Ovid Therapeutics announces results for Phase 1 study of OV329
11h ago
OVID
Ovid Therapeutics Regains Nasdaq Compliance
PremiumCompany Announcements
Ovid Therapeutics Regains Nasdaq Compliance
17d ago
8K
OVID
Ovid Therapeutics’ Promising Pipeline and Strategic Developments Justify Buy Rating
PremiumRatingsOvid Therapeutics’ Promising Pipeline and Strategic Developments Justify Buy Rating
1M ago
OVID
3 Best Stocks to Buy Now, 8/18/2025, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Now, 8/18/2025, According to Top Analysts
2M ago
BZAI
OVID
Ovid Therapeutics: Promising Pipeline and Strong Financial Health Justify Buy Rating
Premium
Ratings
Ovid Therapeutics: Promising Pipeline and Strong Financial Health Justify Buy Rating
2M ago
OVID
Ovid Therapeutics Navigates FDA Disruptions and Government Challenges
PremiumCompany Announcements
Ovid Therapeutics Navigates FDA Disruptions and Government Challenges
2M ago
OVID
Ovid Therapeutics Reports Increased Revenue Amid Challenges
PremiumCompany Announcements
Ovid Therapeutics Reports Increased Revenue Amid Challenges
2M ago
OVID
Ovid Therapeutics: Strategic Advances and Promising Developments Justify Buy Rating
PremiumRatings
Ovid Therapeutics: Strategic Advances and Promising Developments Justify Buy Rating
2M ago
OVID
Ovid Therapeutics Transfers Stock to Nasdaq Capital Market
PremiumCompany Announcements
Ovid Therapeutics Transfers Stock to Nasdaq Capital Market
2M ago
8K
OVID
Ovid Therapeutics reports Q2 EPS (6c), consensus (15c)
PremiumThe FlyOvid Therapeutics reports Q2 EPS (6c), consensus (15c)
2M ago
OVID
Ovid Therapeutics sees cash runway into 2H26
Premium
The Fly
Ovid Therapeutics sees cash runway into 2H26
2M ago
OVID
Ovid Therapeutics initiated with a Buy at Lucid Capital
Premium
The Fly
Ovid Therapeutics initiated with a Buy at Lucid Capital
2M ago
OVID
Ovid Therapeutics transferred with Buy rating at B. Riley
PremiumThe Fly
Ovid Therapeutics transferred with Buy rating at B. Riley
2M ago
OVID
Ovid Therapeutics management to meet with B. Riley
PremiumThe Fly
Ovid Therapeutics management to meet with B. Riley
3M ago
OVID
Ovid Therapeutics Approves Key Proposals at Annual Meeting
PremiumCompany Announcements
Ovid Therapeutics Approves Key Proposals at Annual Meeting
3M ago
8K
OVID
Ovid Therapeutics Sells Ganaxolone Royalties to Immedica
PremiumCompany Announcements
Ovid Therapeutics Sells Ganaxolone Royalties to Immedica
3M ago
8K
OVID
Ovid enters agreement with Immedica for sale of future ganaxolone royalties
PremiumThe FlyOvid enters agreement with Immedica for sale of future ganaxolone royalties
3M ago
OVID
Ovid Therapeutics: Promising Buy Opportunity with OV329 Advancements in Drug-Resistant Epilepsy
Premium
Ratings
Ovid Therapeutics: Promising Buy Opportunity with OV329 Advancements in Drug-Resistant Epilepsy
4M ago
OVID
Positive Outlook for Ovid Therapeutics: Buy Rating Supported by Promising OV329 Drug and Strategic Pipeline Development
Premium
Ratings
Positive Outlook for Ovid Therapeutics: Buy Rating Supported by Promising OV329 Drug and Strategic Pipeline Development
4M ago
OVID

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >